FTC sues Texas anesthesiology provider to bust monopoly

FTC sues Texas anesthesiology provider to bust monopoly


Federal Trade Commission (FTC) Chair Lina Khan testifies before a House Judiciary Committee hearing on “Oversight of the Federal Trade Commission,” on Capitol Hill in Washington, July 13, 2023.

Kevin Wurm | Reuters

The Federal Trade Commission on Thursday sued the largest anesthesiology provider in Texas, claiming the company has wielded monopoly power to drive up prices for patients and boost its profits.

The FTC asked a federal judge in Houston, Texas, to break up U.S. Anesthesia Partners alleged monopoly power and permanently bar the company from engaging in anticompetitive practices.

The agency claims that New York-based private equity firm Welsh, Carson and Stowe founded U.S. Anesthesia Partners in 2012 to pursue an aggressive consolidation strategy that exploited Texas’ fragmented market for anesthesiology providers.

The FTC complaint says that Welsh Carson sought to make USAP the dominant provider in Texas by hoovering up the numerous independent practices that previously competed against each other, keeping prices lower.

CNBC Health & Science

Read CNBC’s latest health coverage:

Welsh Carson and USAP engaged in what the companies called a “roll-up,” buying nearly every large anesthesia practice in Texas, according to the complaint.

Since 2013, USAP has grown from 400 anesthesia providers at 45 health-care facilities to 4,500 providers at 1,100 facilities in 2021.

USAP has established monopoly power in Houston and Dallas, the two largest cities in Texas, and a dominant position in Austin, the state’s capital, according to the complaint.

The company has used its dominance to raise prices, raking in tens of millions dollars, the FTC alleges.

USAP is so powerful in Austin, Dallas and Houston that it can raise prices while still gaining market share because it is difficult for competitors to enter the market, and patients typically cannot forgo anesthesia, according to the complaint.

Dr. Derek Schoppa, a USAP board member, told CNBC that the FTC’s complaint is based on flawed legal theories and a lack of medical understanding about anesthesiology.

“The FTC’s intended outcome threatens to disrupt and restrict patients’ equitable access to quality anesthesia care in Texas and will negatively impact the Texas hospitals and health systems that provide care in underserved communities,” Schoppa said in a statement.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More